# United States SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, D.C. 20549** 

SC]	HF	D	TIT	$\mathbf{F}$	12	$\mathbf{C}$
17(1		ı.	UL	1 1		ιT

Under the Securities Exchange Act of 1934 (Amendment No. 1)\*

# INTRA-CELLULAR THERAPIES, INC.

(Name of Issuer)

Common Stock (Title of Class of Securities)

46116X101 (CUSIP Number)

December 31, 2020 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b)

⊠ Rule 13d-1(c)
□ Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

# CUSIP No. 46116X101

1.	Names of Reporting Persons					
	BB Biotech AG					
2.	. Check the Appropriate Box if a Member of a Group (See Instructions)  (a) ☑ (b) □					
	(a) 🖾	(0)				
3.	. SEC Use Only					
4.	. Citizenship or Place of Organization					
	Switzerland					
		5.	Sole Voting Power			
Number of			0			
Shares		6.	Shared Voting Power			
О	Beneficially Owned by 3,538,419					
Each Reporting		7.	Sole Dispositive Power			
Person 0						
	with: 8. Shared Dispositive Power					
	3,538,419					
9.	Aggrega	ite An	nount Beneficially Owned by Each Reporting Person			
	3,538,419					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares					
11.	. Percent of Class Represented by amount in Row (9)					
	4.4%					
12.	Type of Reporting Person (See Instructions)					
	HC, CO					

# CUSIP No. 46116X101

1.	Names of Reporting Persons				
	Biotech Target N.V.				
	I.R.S. Identification Nos. of above persons (entities only):				
	N/A				
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)				
	(a) ⊠ (b) □				
3.	. SEC Use Only				
4.	Citizenship or Place of Organization				
	Curacao				
		5.	Sole Voting Power		
Number of 0		0			
Shares		6.	Shared Voting Power		
О	neficially vned by		3,538,419		
	Each porting	7.	Sole Dispositive Power		
Person 0					
with: 8. Shared Dispositive Power		Shared Dispositive Power			
	3,538,419				
9.	Aggrega	ite Am	nount Beneficially Owned by Each Reporting Person		
- 10	3,538,419				
10.	. Check if the Aggregate Amount in Row (9) Excludes Certain Shares				
11.	. Percent of Class Represented by amount in Row (9)				
40	4.4%				
12.	Type of Reporting Person (See Instructions)				
	CO				

#### Item 1

- 1(a) Name of Issuer: Intra-Cellular Therapies, Inc.
- 1(b) Address of Issuer's Principal Executive Offices:

430 East 29th Street, Suite 900, New York, NY 10016

#### Item 2

2(a) Name of Person Filing: BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Target N.V. ("Biotech Target").

2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Target N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship: BB Biotech AG: Switzerland

**Biotech Target N.V.: Curacao** 

- 2(d) Title of Class of Securities Common Stock, \$0.0001 par value
- 2(e) CUSIP Number 46116X101

#### Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,538,419
- (b) Percent of class: 4.4%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote 0
- (ii) Shared power to vote or to direct the vote 3,538,419
- (iii) Sole power to dispose or to direct the disposition of 0
- (iv) Shared power to dispose or to direct the disposition of 3,538,419

#### ITEM 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following  $\boxtimes$ .

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Target. Biotech Target is a wholly-owned subsidiary of BB Biotech.

#### **Item 10. Certification**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

#### **SIGNATURES**

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

### **BB Biotech AG**

Date: February 11, 2021	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: February 11, 2021	Ву:	/s/ Ivo Betschart
		Signatory Authority
	Name:	Ivo Betschart
Physical III and NAV	Title:	Signatory Authority
Biotech Target N.V.		
Date: February 11, 2021	Ву:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: <b>February 11, 2021</b>	By:	/s/ Hugo van Neutegem
		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority

# **Exhibit Index**

Exhibit A: Agreement by and between BB Biotech AG and Biotech Target N.V. with respect to the filing of this disclosure statement.\*

\* Previously filed as an exhibit to BB Biotech AG and Biotech Target N.V.'s Schedule 13G filed with the Securities and Exchange Commission on January 30, 2020.